Physician profile

John H Chambers, IV

Nurse Practitioner · Tuscaloosa, AL

NPI 1972567584

$7,907.78

in general payments reported to CMS, 2019-2025

44 companies · $1,685 in 2025

The $1,685 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,328.39
Education$268.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $844.72 2021-2025 Xtandi, Myrbetriq, Veozah
Abbvie INC. $796.56 2021-2025
Sumitomo Pharma America, INC. $737.71 2023-2025 Gemtesa, Orgovyx
Antares Pharma, INC. $582.46 2021-2025 Xyosted, Nocdurna, Tlando
Janssen Biotech, INC. $461.99 2021-2025 Erleada, Akeega
Endo Pharmaceuticals INC. $444.97 2021-2023 Xiaflex, Aveed
Bayer Healthcare Pharmaceuticals INC. $374.20 2021-2025
Urovant Sciences INC $339.80 2021-2022
Pfizer INC. $317.18 2021-2025
Boston Scientific Corporation $262.14 2023-2025 Axonics, Spaceoar Vue System - 10ml, Solyx Sis System
Myriad Genetic Laboratories, INC. $251.06 2021-2024 Prolaris
Axonics, INC. $186.00 2022-2024 Axonics
Progenics Pharmaceuticals, INC. $182.81 2022-2025 Pylarify
Allergan, INC. $149.08 2021
Clarus Therapeutics INC. $125.49 2021
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Procept Biorobotics Corporation $124.99 2023-2025 Aquabeam Robotic System
Hollister Incorporated $123.71 2021-2024 Vapro Plus Pocket
Rochester Medical Corporation $123.66 2021
Urogen Pharma, INC. $104.63 2021-2025 Jelmyto
Abc Home Medical Supply, INC. $100.39 2023-2025
Blue Earth Diagnostics $91.74 2021-2025 Posluma
Endo USA, INC. $91.64 2024-2025 Xiaflex
Medtronic, INC. $86.44 2022-2025 Interstim
Myovant Sciences INC. $86.34 2021-2022
180 Medical, INC. $83.67 2021-2024 Gentlecath Glide, Cure Ultra Catheter
Halozyme INC $76.87 2023
Laborie Medical Technologies Corp. $73.83 2024-2025 Optilume Bph Drug Coated Balloon Catheter
Dendreon Pharmaceuticals LLC $70.93 2021
Olympus America INC. $69.59 2025 Itind System
Coloplast Corp $66.32 2021-2022
Photocure INC $57.52 2021-2022
Ferring Pharmaceuticals INC. $53.16 2024 Adstiladrin
Esperion Therapeutics, INC. $45.35 2021
Immunitybio, INC. $44.47 2025
Baxter Healthcare $43.74 2024 Floseal
Teleflex LLC $42.15 2025 Barrigel
Merck Sharp & Dohme LLC $39.70 2022
Convatec INC. $33.15 2021-2022
Tolmar, INC. $27.60 2023
Astrazeneca Pharmaceuticals LP $23.57 2022
Novartis Pharmaceuticals Corporation $20.20 2021
E.R. Squibb & Sons, L.L.C. $15.62 2022
Provepharm INC. $15.41 2025 Bludigo
Mission Pharmacal Company $15.22 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John H Chambers, IV

$7,907.78

in general payments reported 2019-2025

Years
2021-2025
Top company
Astellas Pharma US INC
Context
The $1,685 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

https://glasscript.com/doctor/10688336/john-h-chambers

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.